Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-Immune Adults: A Phase 1, Double-Blinded Placebo Controlled Dosage Escalation Study.

Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-Immune Adults: A Phase 1, Double-Blinded Placebo Controlled Dosage Escalation Study.

The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naïve adults living in the United States found the recombinant non-glycosylated vaccine a...

Full description

Bibliographic Details
Main Authors: Kwadwo A Koram, Bright Adu, Josephine Ocran, Yaa S Karikari, Susan Adu-Amankwah, Michael Ntiri, Benjamin Abuaku, Daniel Dodoo, Ben Gyan, Karl C Kronmann, Francis Nkrumah
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5028127?pdf=render

Internet

http://europepmc.org/articles/PMC5028127?pdf=render

Similar Items